CL2018001720A1 - Formas polimórficas cristalinas del ácido obeticólico - Google Patents

Formas polimórficas cristalinas del ácido obeticólico

Info

Publication number
CL2018001720A1
CL2018001720A1 CL2018001720A CL2018001720A CL2018001720A1 CL 2018001720 A1 CL2018001720 A1 CL 2018001720A1 CL 2018001720 A CL2018001720 A CL 2018001720A CL 2018001720 A CL2018001720 A CL 2018001720A CL 2018001720 A1 CL2018001720 A1 CL 2018001720A1
Authority
CL
Chile
Prior art keywords
polymorphic forms
crystalline polymorphic
acid
obetolic
obetolic acid
Prior art date
Application number
CL2018001720A
Other languages
English (en)
Inventor
André Steiner
Emilie Jolibois
Melissa Rewolinski
Ralf Gross
Emma Sharp
Fiona Dubas-Fisher
Alex Eberlin
Poulsen Heido Waenerlund
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2018001720A1 publication Critical patent/CL2018001720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A LAS FORMAS CRISTALINAS A, D, F, G E L DEL ÁCIDO OBETICÓLICO. ESTAS FORMAS CRISTALINAS SON ÚTILES EN LA PRODUCCIÓN DE ÁCIDO OBETICÓLICO (EN PARTICULAR SU PURIFICACIÓN), EL CUAL ES UN FÁRMACO ÚTIL PARA EL TRATAMIENTO O LA PREVENCIÓN DE UNA ENFERMEDAD O AFECCIÓN MEDIADA POR FXR, ENFERMEDADES CARDIOVASCULARES O HEPATOPATÍA COLESTÁSICA, Y PARA REDUCIR EL COLESTEROL HDL, PARA REDUCIR LOS TRIGLICÉRIDOS EN UN MAMÍFERO O PARA INHIBIR LA FIBROSIS.
CL2018001720A 2015-12-22 2018-06-22 Formas polimórficas cristalinas del ácido obeticólico CL2018001720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid

Publications (1)

Publication Number Publication Date
CL2018001720A1 true CL2018001720A1 (es) 2018-08-10

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001720A CL2018001720A1 (es) 2015-12-22 2018-06-22 Formas polimórficas cristalinas del ácido obeticólico

Country Status (15)

Country Link
EP (1) EP3394081A1 (es)
JP (1) JP2018538331A (es)
KR (1) KR20180095070A (es)
CN (1) CN108495858A (es)
AU (1) AU2016375566A1 (es)
BR (1) BR112018012590A2 (es)
CA (1) CA3009149A1 (es)
CL (1) CL2018001720A1 (es)
CO (1) CO2018006701A2 (es)
EA (1) EA201891491A1 (es)
IL (1) IL259998A (es)
MX (1) MX2018007776A (es)
PH (1) PH12018501318A1 (es)
SG (1) SG11201805235XA (es)
WO (1) WO2017111979A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972A (zh) * 2020-02-14 2021-08-17 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EA201990211A1 (ru) * 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
KR102546748B1 (ko) * 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
EP3221334B1 (en) * 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
JP6724004B2 (ja) * 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
PT3221331T (pt) * 2014-11-19 2019-12-23 Nzp Uk Ltd Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediários para a produção de moduladores de fxr esteroidais

Also Published As

Publication number Publication date
CO2018006701A2 (es) 2018-07-10
PH12018501318A1 (en) 2019-02-18
KR20180095070A (ko) 2018-08-24
BR112018012590A2 (pt) 2018-12-04
WO2017111979A1 (en) 2017-06-29
IL259998A (en) 2018-07-31
MX2018007776A (es) 2018-08-09
JP2018538331A (ja) 2018-12-27
CA3009149A1 (en) 2017-06-29
EA201891491A1 (ru) 2018-11-30
CN108495858A (zh) 2018-09-04
AU2016375566A1 (en) 2018-07-05
EP3394081A1 (en) 2018-10-31
SG11201805235XA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
CL2018001720A1 (es) Formas polimórficas cristalinas del ácido obeticólico
CO2017001884A2 (es) Polimorfos de selinexor
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CL2018001230A1 (es) Tratamiento de osteoartritis
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
FR3023286B1 (fr) Procede de fabrication de tetrafluoropropene
CL2018000914A1 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular
CL2014001339A1 (es) Procedimiento de preparacion de un compuesto intermediario derivado de 5-fluoro-1h-pirazolopiridina; compuestos intermediarios que participan del mismo y formas cristalinas del compuesto final obtenido, el cual es util en el tratamiento de trastornos cardiocirculatorios.
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CL2018000962A1 (es) Oportunidades para el proceso de aumento de recuperación según se aplica a la producción de molibdeno
DK3305754T3 (da) Fremgangsmåder til fremstilling af højumættet fedtsyre med høj renhed med højt udbytte
CL2018002149A1 (es) Proceso.
BR112016017087A8 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
ES2970503T3 (es) Proceso para la producción de ácido acético
FR3009555B1 (fr) Procede de preparation de peroxydes organiques
FI20156006A (fi) Selektiivinen menetelmä levuliinihapon konversioon gammavalerolaktoniksi
DK3216780T3 (da) Fremgangsmåde til fremstilling af organisk fluorid-alifatisk forbindelse og fremgangsmåde til oprensning af organisk fluorid-alifatisk forbindelse
ES2689371A8 (es) Procedimiento para la preparación de pamoato de pirvinio y sus formas cristalinas
FR3039150B1 (fr) Procede de production de 5-hydroxymethylfurfural en presence de catalyseurs organiques de la famille des thiourees
CL2016000498A1 (es) Proceso para la producción de lactato.
GB201616500D0 (en) Biological process for the conversion of xylans to xylitol
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos